Premium
Adrenal cortical carcinoma
Author(s) -
Venkatesh Swamy,
Hickey Robert C.,
Sellin Rena V.,
Fernandez Jose F.,
Samaan Naguib A.
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890801)64:3<765::aid-cncr2820640333>3.0.co;2-i
Subject(s) - medicine , radiation therapy , surgery , carcinoma , lymph , peritoneum , chemotherapy , abdominal mass , disease , pathology
The records of 110 patients (58 females and 52 males) with histologically proven adrenal cortical carcinoma were studied. Fifty‐six of 110 (50.9%) patients had abdominal symptoms and 33 (30.0%) had a palpable abdominal mass. Surgery for localized and regional disease was associated with a disease‐free survival time of at least 2 years in 28 of the 50 (56%) patients. Abdominal radiotherapy, systemic chemotherapy, and 1,1 dichloro‐2 (O‐chlorophenyl)‐2 (P‐chlorophenyl) ethane (OPDDD) were effective in three of 19 (15.8%) patients, three of 31 (9.7%) patients, and 21 of 72 (29.2%) patients, respectively. Combined radiotherapy and OPDDD did not confer any additional benefit over OPDDD alone. Six of seven patients who received OPDDD as adjuvant treatment are still alive at 1 to 4 years. Distant metastases occurred most commonly in the lungs, liver, peritoneum, lymph nodes, and bones. Only 23% of the patients survived 5 years or more. We conclude that early diagnosis and complete surgical excision offer the best prospects for long‐term survival and that the efficacy of adjuvant OPDDD needs to be evaluated further.